Old Web
English
Sign In
Acemap
>
Paper
>
Lucerastat, an iminosugar for substrate reduction therapy in Fabry disease: preclinical evidence
Lucerastat, an iminosugar for substrate reduction therapy in Fabry disease: preclinical evidence
2017
Richard Welford
Andreas Mühlemann
David A. Priestman
Marco Garzotti
Caroline Deymier
Eric A. Ertel
Marc Iglarz
Daniela Baldoni
Frances M. Platt
Markus R. Probst
Keywords:
Iminosugar
Fabry disease
Biology
Substrate reduction therapy
Diabetes mellitus
Pharmacology
Genetics
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
5
Citations
NaN
KQI
[]